Insulin Resistance & Asthma — USA & UK 1975–2022

Insulin Resistance & Asthma

Prevalence trajectories in the USA and United Kingdom, 1975–2022. Asthma rose sharply from the 1970s through the 1990s before partially plateauing in some age groups. The mechanistic link through airway inflammation and metabolic dysfunction is now well-established in the literature.

Why the two curves don't track each other exactly — even when the correlation is very high:

The solid line shows the percentage of adults with insulin resistance across the entire population — everyone with measurable insulin resistance, regardless of what condition it causes them. Because insulin resistance is the upstream root cause of many different diseases — type 2 diabetes, fatty liver, cognitive decline, cardiovascular disease and more — this curve rises relatively gradually as it reflects a burden shared across all of those outcomes.

The dotted line shows the prevalence of the specific condition studied on this page — in this case, only the people for whom insulin resistance has expressed itself as that particular disease. This curve can rise more steeply because it captures decades of accumulated cases: someone may develop insulin resistance at 35 but not manifest this condition until their 50s, so even a modest early rise in insulin resistance translates into a much larger rise in diagnosed cases years later.

The r value (e.g. r = 0.97) is a correlation coefficient. It doesn't measure whether the two lines are the same height — it measures how consistently they move together over time. An r of 0.97 means that 97% of the rise in this condition over the past five decades is statistically explained by the parallel rise in insulin resistance.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but many other factors are involved.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other contributing causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. At this level, it is difficult to argue that other factors are primarily responsible. The values seen across these studies — consistently 0.90 to 0.97 — place insulin resistance firmly in this category for every condition shown.

United States

USA — Insulin Resistance vs Asthma

1975 – 2022  |  % of population
Insulin Resistance
Asthma Prevalence
United Kingdom

UK — Insulin Resistance vs Asthma

1975 – 2022  |  % of population
Insulin Resistance
Asthma Prevalence
r = 0.89
USA
IR ↔ Asthma
r = 0.85
UK
IR ↔ Asthma
+122%
USA asthma rise
1980 – 2010
~12%
UK current
asthma prevalence
Mechanistic note: Asthma and insulin resistance share a documented inflammatory pathway. Hyperinsulinaemia promotes pro-inflammatory cytokines (IL-6, TNF-α) that sensitise airway tissue. Obesity-related asthma — now a recognised clinical subtype — is closely linked to insulin resistance. The UK's asthma rate stabilised somewhat after the early 2000s, mirroring a partial plateau in new diagnoses, while USA adult asthma has continued rising. Both trajectories closely follow metabolic trends.
Data sources
Asthma USA: CDC/NHIS 1980–2022. Current asthma prevalence: 3.6% (1980) → 7.3% (2001) → 8.2% (2022, adults). Children peaked ~10% early 2000s. American Lung Association Asthma Trends Brief 2023.
https://www.cdc.gov/asthma/asthmadata.htm
https://www.lung.org/research/trends-in-lung-disease/asthma-trends-brief/trends-and-burden
Asthma UK: Asthma + Lung UK; NHS Digital; "50 years of asthma: UK trends from 1955–2004" (BMJ); NHS Health Survey England 2003–2021. UK prevalence ~8% (1975) rising to peak ~15% (late 1990s), current ~12% of all ages.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2111282/
https://www.asthma.org.uk/about/media/facts-and-statistics/
Insulin Resistance USA: NHANES III 1988–94; NHANES 1999–2018 (Hirode & Wong, JAMA 2020); Frontiers meta-analysis 2025.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11601873/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12411212/
Scroll to Top
MENU
For Radiant Health